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Abstract
Purpose. To enumerate lessons from studying 4292 patients with rhabdomyosarcoma (RMS) in the Intergroup Rhabdomy-
osarcoma Study Group (IRSG, 1972± 1997).
Patients. Untreated patients < 21 years of age at diagnosis received systemic chemotherapy, with or without irradiation (XRT)
and/or surgical removal of the tumor.
Methods. Pathologic materials and treatment were reviewed to ascertain compliance and to confirm response and relapse status.
Results. Survival at 5 years increased from 55 to 71% over the period. Important lessons include the fact that extent of disease
at diagnosis affects prognosis. Re-excising an incompletely removed tumor is worthwhile if acceptable form and function can
be preserved. The eye, vagina, and bladder can usually be saved. XRT is not necessary for children with localized, completely
excised embryonal RMS. Hyperfractionated XRT has thus far not produced superior local control rates compared with
conventional, once-daily XRT. Patients with non-metastatic cranial parameningeal sarcoma can usually be cured with local-
ized XRT and systemic chemotherapy, without whole-brain XRT and intrathecal drugs. Adding doxorubicin, cisplatin,
etoposide, and ifosfamide has not significantly improved survival of patients with gross residual or metastatic disease beyond
that achieved with VAC (vincristine, actinomycin D, cyclophosphamide) and XRT. Most patients with alveolar RMS have a
tumor-specific translocation. Mature rhabdomyoblasts after treatment of patients with bladder rhabdomyosarcoma are not
necessarily malignant, provided that the tumor has shrunk and malignant cells have disappeared.
Discussion. Current IRSG-V protocols, summarized herein, incorporate recommendations for risk-based management. Two
new agents, topotecan and irinotecan, are under investigation for patients who have an intermediate or high risk of recurrence.
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Introduction
Soft-tissue  sarcomas  comprise  the  fifth  most
common  type  of  childhood  solid  tumor,  and
rhabdomyosarcoma (RMS)  is  the  most  common
form encountered in the first two decades of life. The
disease can arise at any site and in any tissue in the
body  except  bone.  There  are  several  histologic10 R. B. Raney et al.
subtypes: embryonal  RMS  (ERMS),  the  botryoid
and  spindle-cell  variants  of  ERMS,  and  alveolar
RMS (ARMS). ERMS is approximately three times
more frequent than ARMS. In addition, RMS can
metastasize to any tissue or organ in the body. All of
these features lead to a myriad of forms of the disease,
rendering it difficult to classify patients into homoge-
neous groups.
The  Intergroup  Rhabdomyosarcoma  Study
Group (IRSG) was formed under the auspices of
the National Cancer Institute in 1972 to investigate
the  therapy  and  biology  of  RMS  and
undifferentiated  sarcoma  (UDS)  in  previously
untreated patients less than 21 years of age. The
patients were recruited from member institutions of
the  three  cooperative  pediatric  cancer  treatment
groups  existing  at  the  time.  Since  then,  five
successive clinical protocols involving 4292 eligible
patients have been completed: IRS-I, 1972± 1978;
IRS-II,  1978± 1984;  IRS-III,  1984± 1991,  IRS-IV
Pilot  (for  patients  with  advanced  disease  only),
1987± 1991; and IRS-IV, 1991± 1997.1± 7 Many of
the several  trials conducted within each  protocol
were randomized. In addition, the accumulation of
a  large  number of  cases of  relatively  uncommon
tumors  has  led  to  acquisition  of  important  new
information about the evolution of the disease and
its biology.
The purposes of this article are: (1) to summarize
the important lessons learned from the IRSG proto-
cols over the past 25 years; and (2) to outline the cur-
rent  therapeutic  approaches  for  newly  diagnosed
patients who may be  eligible for treatment on the
IRS-V study. IRS-V was opened in 1997 for patients
with low-risk disease (i.e. with a good prognosis for




Patients are separated into four groups based on the
extent of the disease as determined by clinical and
radiographic imaging studies, along with a sample of
bone marrow and tissue for pathologic examination
taken from the primary tumor site. A cerebrospinal
fluid sample is required for patients with cranial par-
ameningeal tumors. Table 1 presents the surgical±
pathologic  grouping  system,  which  categorizes
patients according to the extent of disease remaining
after  the  initial  surgical  procedure(s)  but  before
beginning  chemotherapy  and  radiation  therapy
(XRT). During the evolution of the IRSG protocols,
it became apparent that there was a need to adopt a
pre-clinical staging system that did not depend on the
surgeon’s decision of how much tissue to remove or
on pathologic assessment of the specimen. The stag-
ing system was developed as a modified tumor± node±
metastasis system, similar to classifications used by
the International Union Against Cancer (UICC) and
by our European colleagues.8
Table 2 displays this staging system, which sepa-
rates patients by site of the primary tumor, tumor
size, and the presence or absence of tumor-involved
regional lymph nodes and of distant metastases. Cur-
rently,  the  staging  and  grouping systems  and  the
tumor histologic subtype are all used to make deci-
sions about treatment. Patients are placed into cate-
gories according to the prediction of survival, using
the  staging  system and  histologic subtype;  various
combinations of chemotherapeutic agents are admin-
istered accordingly. The grouping system categorizes
patients by the amount of residual disease after initial
surgery;  XRT  is  administered  according  to  each
patient’s group and histologic subtype. 
Table 1. IRSG surgical± pathologic grouping system
Group Definition
I Localized tumor, completely removed with pathologically clear margins and no regional lymph node involvement
II Localized tumor, grossly removed with (a) microscopically involved margins, (b) involved, grossly resected 
regional lymph nodes, or (c) both
III Localized tumor, with gross residual disease after grossly incomplete removal, or biopsy only
IV Distant metastases present at diagnosis
Table 2. IRSG staging system





Any size N0, N1 M0
2 All other sites £  5 N0 M0





4 Any site Any size N0 or N1 M1
PM, Parameningeal; GU, genito-urinary; N0, regional nodes not clinically involved by tumor; N1, regional nodes clini-
cally involved by tumor; M0, no distant metastases; M1, distant metastases at diagnosis.Lessons from IRS-1 through -IV and the IRS-V Study 11
Eligibility and quality control
The following criteria have been used throughout all
IRSG  protocols.  Newly  diagnosed,  previously
untreated patients with RMS or UDS are eligible pro-
vided that they are less than 21 years of age at the com-
mencement of therapy and are available for follow-up.
In addition, therapy must be initiated within 42 days
after the initial surgical procedure that provided diag-
nostic  tissue.  All  pathologic  materials  are  reviewed
centrally, to ascertain eligibility. The IRSG surgeons
review  the  operative  procedures  and  information
regarding grouping and staging. The IRSG radiation
oncologists and the Quality Assurance Review Center
(Providence, RI, USA) review all material related to
XRT. The IRSG chemotherapists review the details of
systemic treatment and assess protocol compliance.
All of these reviews contribute to quality control.
Results
The  results  of  IRS-I  to  IRS-IV  have  been  pub-
lished.1± 7 The following presents the major lessons
that  have  been learned as experience has accrued.
These lessons are classified as surgical, radiothera-
peutic,  chemotherapeutic,  and  pathobiologic,  and
will be presented in that order.
Surgery
1. Patients with localized, completely resected dis-
ease (group I) generally have the best prognosis
for 5-year failure-free survival (FFS) and overall
survival.  Patients  with  metastases  at  diagnosis
(group IV) have the worst outlook, and those with
group  II  and  III  disease  have  an  intermediate
prognosis. Thus, it has been preferable to try to
remove  all  visible  tumors,  if  feasible  without
excessive morbidity.
2. When a lesion has been excised without knowl-
edge that it is malignant, wide re-excision is indi-
cated, if feasible cosmetically and functionally, in
order to obtain tumor-free margins.9 This is par-
ticularly applicable to patients with primary tumor
of the extremities.10 Patients with group I ERMS
do not need post-operative XRT.11
3. It is desirable to preserve organ function and thus
spare such structures as the eye, vagina, and blad-
der. Furthermore, patients with tumor at or near
these sites have a good prognosis. Primary chem-
otherapy followed by radiation therapy is the rec-
ommended approach. Delayed excision of initially
unresected  tumor  may  improve  prognosis  by
changing  a  partial  response  into  a  complete
response after initial shrinkage of the tumor by
chemotherapy, with or without XRT.12
4. There is a relationship between age at diagnosis
and  likelihood of  regional lymph  node involve-
ment in boys  with  non-metastatic paratesticular
rhabdomyosarcoma. Event-free survival in IRS-IV
was better for boys younger than 10 years of age,
as the nodal relapse rate was lower than in those 10
years of age and older. We now recommend per-
forming  a  modified  ipsilateral  retroperitoneal
lymph-node dissection in older boys who have no
clinical evidence of regional node involvement. If
the nodes are uninvolved, cyclophosphamide and
XRT  are  withheld;  if  tumor  is  present  in  the
nodes, cyclophosphamide and XRT are given in
addition to vincristine and actinomycin D.13
Radiation therapy (XRT)
1. There is no evidence to show benefit from giving
radiation to patients with completely resected, local-
ized lesions (group I), provided that the histologic
subtype is ERMS.11 Graded doses of irradiation are
appropriate  for  all  other  patients,  based  on  the
patient’s group at the time of study entry. Volumes
to be irradiated include the pre-treatment primary
tumor and regional lymph-nodal area, if involved.
Patients with group IV disease receive XRT to both
the primary site and to the sites of metastases, within
the limits of bone-marrow tolerance.
2. A recent analysis of patients with group II disease
in IRS-I to IRS-IV has shown improved outcome
in IRS-III and IRS-IV, perhaps due to intensified
therapy.14
3. Local failure rates for patients with group III dis-
ease  in  the  IRS-III  and  IRS-IV  studies  have
recently been reviewed. The rates have remained
stable or improved. In IRS-IV, local failure rates
were 2% in orbit primary sites, 16% in cranial par-
ameningeal sites, and 12% in other head/neck sites.
Local failure rates were 7% in extremity sites, 19%
in genitourinary sites, and 14% in other sites.15
4. Thus far, there is no indication that giving hyper-
fractionated XRT to 59.4 Gy in two daily fractions
of 1.1 Gy, with a 6-hour interfractional interval,
will result in a better local-regional control rate
among children with group III tumors than that
obtained with 50.4 Gy in 1.8 fractions daily.16
5. Current IRSG results suggest that most patients
with  cranial  parameningeal  sarcoma,  including
those with localized intracranial extension in con-
tiguity with the primary tumor at diagnosis, can be
successfully managed with systemic chemother-
apy and XRT. Radiation therapy is directed to the
primary  tumor,  including any  extension,  along
with  a  2  cm  margin,  to  include  the  adjacent
meninges. Whole-brain XRT and intrathecal anti-
cancer agents are not necessary in the absence of
diffuse meningeal involvement or multiple intrac-
ranial metastases.17
Chemotherapy
1. Data  from  IRS-I,  IRS-II,  and  IRS-III  in  1431
patients  indicate  that  there  is  no  benefit  from12 R. B. Raney et al.
adding doxorubicin (DOX) to the combination of
vincristine, actinomycin D, and cyclophosphamide
(VAC) in patients with group III and IV disease,
whether analyzed together or within group III and
group IV categories individually.1± 3 The addition
of DOX and cisplatin with or without etoposide to
the VAC regimen has not improved outcome for
patients with advanced disease in IRS-III.3
2. Data from IRS-IV indicate that the current stand-
ard combination of VAC, with cyclophosphamide
at 2.2 g/m2 per dose with GCSF is equally effica-
cious with regard to failure-free and overall sur-
vival as are VAI (vincristine, actinomycin D, and
ifosfamide) and VIE (vincristine, ifosfamide, and
etoposide).7
3. Escalation of cyclophosphamide dose from 0.9 g/
m2 in IRS-III to 2.2 g/m2 in IRS-IV has improved
the  failure-free survival  of  patients  with  ERMS
but not those with ARMS or UDS.18
4. Topotecan is a relatively new agent with the abil-
ity to disrupt topoisomerase I and thereby inhibit
DNA replication. It is active in newly diagnosed
patients with metastatic RMS, and can be given in
combination with VAC.19
Pathology and biology
1. The results of the IRS-I and IRS-II studies indi-
cated  that  patients  with  alveolar  RMS  have  a
worse  outlook  than  those  with  embryonal
RMS.20,21 Treatment was then intensified, and
outcome was improved for such patients in IRS-
III. Many of the patients with ARMS are older
patients with extremity primary tumors, both of
which  are  unfavorable  prognostic  factors.21
Patients with UDS also have a worse outlook than
their counterparts with ERMS.20,21
2. In patients with ERMS of the bladder, the demon-
stration of maturing rhabdomyoblasts in sequen-
tial  biopsies  from  the  primary  tumor  after
shrinkage following chemotherapy and radiation
therapy does not necessarily signify the presence of
malignant cells.22 Thus, the current recommenda-
tions are not to use aggressive surgical interven-
tions, but to continue chemotherapy and follow
with repeated imaging studies along with biopsy
when indicated, in order to preserve the bladder.
3. Molecular genetic studies have shown two con-
sistent translocations in tumors from the majority
of patients with ARMS. The t(2;13) translocation
often occurs in older patients who have a worse
outcome than their younger counterparts with the
t(1;13)  translocation.  Members  of  this  latter
group are often infants who have a better progno-
sis  than  would  be  expected  otherwise.23,24  To
date, there has been no consistently present trans-
location identified in ERMS.
4. Studies of the expression of P-glycoprotein25 and
of  alterations  in  the  p53  gene26,27  may  yield
implications for the future therapy and prognosis
of patients with RMS. It is possible that other
substances  and  as  yet  undiscovered  genetic
changes will also have implications for directing
future research in RMS. It is necessary to obtain
fresh  tumor  samples  at  diagnosis  to  elucidate
answers to basic biologic questions.
5. There  is  a  small  but  appreciable  incidence  of
second malignant neoplasms arising in children
who have survived RMS.28,29 The risk is highest
in patients treated with both XRT and alkylating
agents, especially melphalan.30 Thus, all patients
with RMS and UDS should be followed for many
years  to  elucidate  more  precisely the  incidence
and proper management of this complication.
The IRS-V Study
The IRS-V study combines group, stage, and histo-
logic subtype to allocate patients to three different
therapeutic protocols according to risk of recurrence.
Low-risk patients have an estimated 3-year FFS rate
of 88%; intermediate-risk patients have an estimated
3-year FFS rate of 55± 76%, and high-risk patients
have a 3-year FFS rate of < 30%. Multidisciplinary
treatment is recommended as defined by histologic
subtype and primary site, as well as the extent of dis-
ease at diagnosis and response to treatment. The goal
is to achieve local control with preservation of form
and function. The Appendix displays the elements of
the protocols for the three risk groups and indicates
therapy for each.
Chemotherapy
Low-risk patients have localized ERMS in favorable
sites (stage 1) or in unfavorable sites (stages 2 and 3)
that has been grossly completely removed, without
(group I) or with (group II) microscopic residual dis-
ease and/or resected, tumor-involved regional lymph
nodes.  The  patients  with  the  best  prognosis  are
placed in subgroup A and receive VA with or without
XRT. The  others, placed in subgroup B, received
VAC  ±  XRT  (see  Appendix).  Intermediate-risk
patients have localized ARMS or UDS (stages 1± 3)
or ERMS (stages 2 and 3) with gross residual disease
(group III), or ERMS with metastases (group IV) at
< 10 years of age at diagnosis. They are randomized
to receive VAC or VAC alternating with vincristine
and  cyclophosphamide plus  topotecan,  along  with
XRT. High-risk patients have ERMS at ‡  10 years of
age, or ARMS or UDS at any age < 21 years, with
metastases at diagnosis (group IV). They receive a
trial of irinotecan31 over 6 weeks followed by VAC.
Irinotecan is  continued  at  intervals  for  those  who
have responded to it initially, but is omitted for non-
responders. High-risk patients with cranial parame-
ningeal tumors and meningeal impingement at diag-
nosis receive VAC without irinotecan.Lessons from IRS-1 through -IV and the IRS-V Study 13
Radiation therapy
Patients with completely excised ERMS (i.e. group I)
receive no XRT. However, patients with completely
excised (group I) ARMS and UDS receive XRT to
the primary site.11 Other patients receive XRT as a
function of group, histologic subtype and status of
regional  lymph  nodes  and/or  distant  metastases.
Patients with metastases receive XRT to the primary
tumor and to sites of metastases, within the limits of
bone marrow tolerance.
Surgery
The  incidence  of  tumor-involved  regional  lymph
nodes in patients with primary tumors of the extrem-
ity may be higher than initially suspected.32 Sentinel
lymph-node mapping, using a vital dye such as meth-
ylene blue along with radiolabelled technetium sulfur
colloid, can localize the regional node most likely to
contain tumor cells.33 The surgeon can then remove
the labeled node so that the pathologist can deter-
mine whether tumor cells are present. If they are, the
node-bearing region should be irradiated. The utility
of lymph-node mapping will be examined in IRS-V.
For  patients  whose  tumors  are  initially  deemed
unresectable,  a  second-look  procedure  should  be
considered  after  initial  chemotherapy.  Recom-
mended local control measures are specified by pri-
mary site.
Pathology and biology
There is much to be learned about the biology of
these tumors. Both fresh tissue and frozen tissue are
necessary for ongoing studies and for new investiga-
tion in molecular biology.
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